(Total Views: 469)
Posted On: 02/11/2020 2:19:57 PM
Post# of 72440
meant to say yesterday's event
---
https://www.bio.org/events/bio-ceo-investor-c...ons/628944
Despite a record number of large deals across the pharmaceutical and biotechnology landscape, market indicators are pointing toward a noticeable shift in the appetite for global deal-making across the industry. As the pool of high-valued assets becomes smaller, will signs point to a drastic increase in smaller deals for larger pharma companies looking to solidify their balance sheets across core therapeutic areas? How does a strong public market with a well-capitalized pool of young biotech targets that don’t need to be forced into an early buyout impact this hypothetical M&A shift? This session will feature experienced voices explaining the public perspective for a potentially active year within pharma and biotech deal-making.
---
https://www.bio.org/events/bio-ceo-investor-c...ons/628944
Despite a record number of large deals across the pharmaceutical and biotechnology landscape, market indicators are pointing toward a noticeable shift in the appetite for global deal-making across the industry. As the pool of high-valued assets becomes smaller, will signs point to a drastic increase in smaller deals for larger pharma companies looking to solidify their balance sheets across core therapeutic areas? How does a strong public market with a well-capitalized pool of young biotech targets that don’t need to be forced into an early buyout impact this hypothetical M&A shift? This session will feature experienced voices explaining the public perspective for a potentially active year within pharma and biotech deal-making.
(6)
(1)Scroll down for more posts ▼
